{
    "clinical_study": {
        "@rank": "159571", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multi-center observational study will evaluate the use of Xeloda (capecitabine) in\n      patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced\n      gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving\n      treatment with Xeloda according to product label will be followed for up to 10 months."
        }, 
        "brief_title": "An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer, Colorectal Cancer, Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Colorectal Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with metastatic colorectal cancer, colon cancer in the adjuvant setting,\n             advanced gastric cancer or breast cancer who are candidates for receiving Xeloda\n             according to product label\n\n        Exclusion Criteria:\n\n          -  Contraindications according to label and off-label use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced\n        gastric cancer or breast cancer receiving Xeloda"
            }
        }, 
        "enrollment": {
            "#text": "664", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664494", 
            "org_study_id": "ML25281"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wien", 
                    "country": "Austria", 
                    "zip": "1090"
                }
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of treatment cycles in routine clinical practice", 
            "safety_issue": "No", 
            "time_frame": "approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Mean dosage over all indications", 
            "safety_issue": "No", 
            "time_frame": "approximately 2 years"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}